Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 11
Submit an article Journal homepage
49
Views
6
CrossRef citations to date
0
Altmetric
Research Article

The Combination of Chemotherapy and Systemic Immunotherapy and the Concept of Cure in Murine Leukemia and Lymphoma

Kyriaki Dunussi-Joannopoulos Wyeth Research, 200 Cambridge Park Drive, Cambridge MA, 02140, USA
Pages 2075-2082 | Published online: 01 Jul 2009

  • Willman, C.L. (1997) "The prognostic significance of the expression and function of multidnig resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program", Semin. Hematol. 34, 25-33.
  • van der Kolk, D.M., de Vries, E.G., van Putten, W.J., Verdonck, L.K. Osscnkoppele, G.J., Verhoef, G.E. and Vellenga, E. (2000) "P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia", Clin. Cancer Res. 6, 3205-3214.
  • Hiddemann, W. and Buchner, T. (2001) "Current status and perspectives of therapy for acute myeloid leukemia", Semin. Hematol. 38, 3-9.
  • Lowenberg, B., Downing, J.R. and Burnett, A. (1999) "Acute myeloid leukemia", N. Engl. J. Med. 341, 1051-1062.
  • Appelbaum, F.R. and Kopecky, K.J. (1997) "Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group", Cancer 80, 2199-2204.
  • Appelbaum, F.R., Rowe, J.M., Radich, J. and Dick, J.E. (2001) "Acute myeloid leukemia", Hematalngy (Am. Soc. Hematol. Educ. Program), 62-86.
  • Lowenberg, B. (2001) "Managing therapy in older adult patients with acute myeloid leukemia", Semin. Hematol. 38, 10-16.
  • Walther, M.M., Yang, J.C., Pass, H.I., Linehan, W.M. and Rosenberg, S.A. (1997) "Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma", J. UroI. 158, 1675-1678.
  • Kawakami, Y. (2000) "New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system", Cornea 19, S2-S6.
  • Kolb, H.-J., Schattenberg, A., Goldman, J.M., Hertenstein, B., et al., (1995) "Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients", Blood 86, 2041-2050.
  • Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, P.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhorn, J.H. and White, D.E. (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", Nat. Med. 4, 321-327.
  • Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", Nat. Med. 4, 328-332.
  • Runger, T.M., Klein, C.E., Becker, J.C. and Brocker, E.B. (1994) "The role of genetic instability, adhesion, cell motility, and immune escape mechanisms in melanoma progression", Curr. Opin. Oncol. 6, 188-196.
  • Reynolds, T.Y. Rockwell, S. and Glazer, P.M. (1996) "Genetic instability induced by the tumor microenvironment", Cancer Res. 56, 5754-5757.
  • Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1998) "Genetic instabilities in human cancers", Nature 396, 643-649.
  • Duesberg, P., Rausch, C., Rasnick, D. and Hehlmann, R. (1998) "Genetic instability of cancer cells is proportional to their degree of aneuploidy", Proc. Natl Acad. Sci. USA 95, 13692-13697.
  • Wang, J., Saffold, S., Cao, X., Krauss, J. and Chen, W. (1998) "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", J. Immunol. 161, 5516-5524.
  • Kugler, A., Stuhler, G., Waiden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C.A., Becker, V. Gross, A.J., Hemmerlein, B., Kanz, L., Muller, G.A. and Ringen, R.H. (2000) "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", Nat. Med. 6, 332-336.
  • Prehn, R.T. and Main, J.M. (1957) "Immunity to methylcholanthrene-induced sarcomas", J. Natl Cancer Inst. 18, 769-778.
  • Prehn, R.T. (1964) "Role of immunity in the biology of cancer", Proc. Natl Cancer Conf. 5, 97-104.
  • Prehn, R.T. (1965) "Cancer antigens in tumors induced by chemicals", Fed. Proc. 24, 1018-1022.
  • Hewitt, H.B., Blake, E.R. and Walder, A.S. (1976) "A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin", Br. J. Cancer 33, 241-259.
  • Boon, T., Cerottini, J.C., Van den Eynde, B., Van der Bruggen, P. and Van Pel, A. (1994) "Tumor-antigens recognized by T lymphocytes", Annu. Rev. Immunol. 12, 337-365.
  • Van Pel, A., van der Bruggen, P., Coulie, P.C., Brichard, V.G., Lethe, B., van den Eynde, B., Uyttenhovc, C., Renauld, J.C. and Boon, T. (1995) "Genes coding for tumor antigens recognized by cytolytic T lymphocytes", Immunol. Rev. 145, 229-250.
  • Chen, L., Linsley, P.S. and HellstrU+00f6m, K.E. (1993) "Costimulation of T cells for tumor immunity", Immunol. Today 14, 483-486.
  • Allison, J.P., Hurwitz, A.A. and Leach, D.R. (1995) "Manipulation of costimulatory signals to enhance antitumor T-cell responses", Curr. Opin, Immunol 7, 682-686.
  • Liebowitz, D.N, Lee, K.P. and June, C.H. (1998) "Costimulatory approaches to adoptive immunotherapy", Curr. Opin. Oncol 10, 533-541.
  • Colombo, M.P. and Forni, G. (1994) "Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?", Immunol. Today 15, 48-51.
  • Pardoll, D.M. (1995) "Paracrine cytokine adjuvants in cancer immunotherapy", Annu. Rev. Immunol. 13, 399-415.
  • Musiani, P., Modesli, A., Giovarelli, M., Cavallo, F., Colombo, M.P., Lollini, P.L. and Forni, G. (1997) "Cytokines, tumour-cell death and immunogenicity: a question of choise", Immunol. Today 18, 32-37.
  • Homey, B., Muller, A. and Zlotnik, A. (2002) "Chemokines: agents for the immunotherapy of cancer?", Nat. Rev. Immunol. 2, 175-184.
  • Liu, Y. and Linsley, P.S. (1992) "Costimulation of T-cell growth", Curr. Opin. Immunol. 4, 265-270.
  • Linsley, P.S. and Ledbetter, J.A. (1993) "The role of the CD28 receptor during T cell responses to antigen", Annu. Rev. Immunol. 11, 191-212.
  • Coyle, A.J. and Gutierrez-Ramos, J.C. (2001) "The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function", Nat. Immunol. 2, 203-209.
  • Carreno, B.M. and Collins, M. (2002) "The B7 family of Ligands and its receptors: new pathways for costimulation and inhibition of immune responses", Annu. Rev. Immunol. 20, 29-53.
  • Scbwartz, R.H. (1990) "A cell culture model for T lymphocyte clonal anergy", Science 248, 1349-1356.
  • Schwartz, R.H. (1992) "Costimulation of T lymphocytes: the role of CD28. CTLA-4, and B7//BB1 in interleukin-2 production and immunotherapy", Cell 71, 1065-1068.
  • June, C.H., Bluestone, J.A., Nadler, L.M. and Thompson, C.B. (1994) "The B7 and CD28 receptor families", Immunol. Today 15, 321-331.
  • Boussiotis, V.A., Freeman, G.J., Gribben, J.G. and Nadler, L.M. (1996) "The role of B7-1/B7-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response", Immunol. Rev 153, 5-26.
  • Schwartz, R.H. (1996) "Models of T cell anergy: is there a common molecular mechanism?", J. Exp. Med. 184, 1-8.
  • Boussiotis, V.A., Gribben, J.G., Freeman, G.J. and Nadler, L.M. (1994) "Blockade of the CD28-costimulatory pathway: a means to induce tolerance", Curr. Opin. Immunol. 6, 797-807.
  • Yoshinaga, S.K., Whoriskey, J.S., Khare, S.D., Sarmiento, U., Guo, J., Horan, T. Shih, G., Zhang, M., Coccia, M.A., Kohno, T., Tafuri-Bladt, A., Brankow, D., Campbell, P., Chang, D., Chiu, L., Dai, T., Duncan, G., Elliott, G.S., Hui, A., McCabe, S.M., Scully, S., Shahinian, A., Shaklee, C.L., Van, G., Mak, T.W., et al., (1999) "T-cell co-stimulation through B7RP-1 and ICOS", Nature 402, 827-832.
  • Swallow, M.M., Wallin, J.J. and Sha, W.C. (1999) "B7h, a novel costimulalory homolog of B7.1 and B7.2, is induced by TNFalpha", Immunity 11, 423-432.
  • Ling, V., Wu, P.W., Finnerty, H.F., Bean, K.M., Spaulding, V, Fouser, L.A., Lieonard, J.P., Hunter. S.E., Zollner, R., Thomas, J.L., Miyashiro, J.S., Jacobs, K.A. and Collins, M. (2000) "Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor", J. Immunol. 164, 1653-1657.
  • Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chemova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., Horton, H.F., Fouser, L., Carter, L., Ling, V., Bowman, M.R., Caneno, B.M., Collins, M., Wood, C.R. and Honjo, T. (2000) "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation", J. Exp. Med. 192, 1027-1034.
  • Dong, H., Zhu, G.,Tarnada, K. and Chen, L. (1999) "B7-HI, a third member of the B7 family, co-stimulates T-cell proliferation and intedeukin-10 secretion", Nat. Med. 5, 1365-1369.
  • Latchman, Y., Wood, C.R., Chemova, T., Chaudhary, D., Borde, M., Chemova, I., Iwai, Y., Long, A.J., Brown, J.A., Nunes, R., Greenfield, E.A., Bourque, K., Bousstotis, V.A., Carter, L.L., Carreno, B.M., Malenkovich, N., Nishimura, H., Okazaki, T., Honjo, T., Sharpe, A.M. and Freeman, G.J. (2001) "PD-L2 is a second ligand for PD-I and inhibits T cell activation", Nat. Immunol. 2, 261-268.
  • Chapoval, A.I., Ni. J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., Dong, H., Sica, G.L., Zhu, G., Tamada, K. and Chen, L. (2001) "B7-H3: a cmtimulatory molecule for T cell activation and IFN-gamma production", Nat. Immunol. 2, 269-274.
  • Allison, J.P. (1994) "CD28-B7 interactions in T-cell activation", Curr. Opin. Immunol. 6, 414-419.
  • Chambers, C.A., Krummel, M.F., Boitel, B., Hurwitz, A., Sullivan, T.J., Fournier, S., Cassell, D., Brunner, M. and Allison, J.P. (1996) "The role of CTLA-4 in the regulation and initiation of T-cell responses", Immunol. Rev. 153, 27-46.
  • Krummel, M.F. and Allison, J.P. (1996) "CTLA-4 engagement inhibits 1L-2 accumulation and cell cycle progression upon activation of resting T cells", J. Exp. Med. 183, 2533-2540.
  • Thompson, C.B. and Allison, J.P. (1997) "The emerging role of CTLA-4 as an immune attenuator", Immunity 7, 445-450.
  • Chambers, C.A., Kuhns, M.S., Egen, J.G. and Allison, J.P. (2001) "CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy", Annu. Rev. Immunol. 19, 565-594.
  • Allison, J.P., Hurwitz, A.A. and Leach, D.R. (1995) "Manipulation of costimutatory signals to enhance antitumor T-cell responses", Curr. Opin. Immunol 7, 682-686.
  • Chen, L., Ashe, S., Brady, W.A., Hellström, L., Hellström, K.E., Ledbetter, J-A., McGowan, P. and Linsley, P. (1992) "Costimulation of antitumor immunity by the B7 counterrcceptor for the T lymphocyte molecules CD28 and CTLA-4", Cell 71, 1093-1102.
  • Townsend, S.E. and Allison, J.P. (1993) "Tumor rejection after direct costimualtion of CD8+T cells by B7-trarsfected melanoma cells", Science 259, 368-370.
  • Matulonis, U.A., Dosiou, C., Lamont, C., Freeman, G.J., Mauch, P., Nadler, L.M. and Griffin, J.D. (1995) "Role of B7-1 in mediating an immune response to myeloid leukemia cells", Blood 85, 2507-2515.
  • Dunussi-Joannopoulos, K., Weinstein, H.J., Nickerson, P.W., Strom, T.B., Burakoff, S.J., Croop, J.M. and Arced, R.J. (1996) "Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML", Blood 87, 2938-2946.
  • Dranoff, G. and Mulligan, R.C. (1995) "Gene transfer as cancer therapy", Adv. Immunol. 58, 417-454.
  • Dunussi-Joannopoulos, K., Krenger, W., Weinstein, H.J., Ferrara, J.L.M. and Croop, J.M. (1997) "CD8+ T-cells activated during the course of murine AML elicit therapeutic responses to late B7 vaccines after cytoreductive treatment", Blood 89, 2915 -2924.
  • Sturmhoefel, K., Lee, K., Gray, G.S., Thomas, J., Zollner, R., O'Toole, M., Swiniarski, H., Domer, A. and Wolf, S.F. (1999) "Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant", Cancer Res. 59, 4964-4972.
  • Runyon, K., Lee, K., Zuberek, K., Collins, M., Leonard, J.P. and Dunussi-Joannopoulos, K. (2001) "The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses", Blood 97, 2420-2426.
  • Burnett, A. K. and Eden, O.B. (1997) "The treatment of acute leukemia", Lancet 349, 270-275.
  • Gallucci, S., Lolkenm, M. and Maizinger, P. (1999) "Natural adjuvants: endogenous acrtivators of dendritic cells", Nat. Med. 5, 1249-1255.
  • Sauter, B., Albert, M.L., Francisco, L., Larsson, M., Somersan, S. and Bhardwaj, N. (2000) "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells [see comments]", J. Exp. Med. 191, 423-434.
  • Banchereau, J. and Steinman, R.M. (1998) "Dendritic cells and the control of immunity", Nature 392, 245-252.
  • Runyon, K., Lee, K., Leonard, J.P., Collins, M. and Dunussi-Joannopoulos, K. (2000) "Fe?R engagement in seid macrophages by soluble B7.2-IgG fusion protein induces upregulation of CD40 and other activation-related molecules", RLSEB J. 14(6), A1004.
  • Freeman, G.J., Lombard, D.B., Ginuni, C.D., Brod, S.A., Lee, K., Laning, J.C., Hafler, D.A., Dorf, M.E., Gray, G.S., Reiser, H., et al., (1992) "CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production", J. Immunol. 149, 3795-3801.
  • Lindsten, T., Lee, K.P., Harris, E.S., Petryniak, B., Craighead, N., Reynolds, P.J., Lombard, D.B., Freeman, G.J., Nadler, L.M., Gray, G.S, et al., (1993) "Characterization of CTLA-4 structure and expression on human T cells", J. Immunol. 151, 3489-3499.
  • Zhou, H., Sequeira, M., Goad, M.E., Erickson, J., Wong, A., Clark, E., Dunussi-Joannopoulos, K., Li, R.C., Friedrich, S., Hayes, L.L. and Wolf, S.F. (2001) "Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy", Clin. Immunol. 101, 303-314.
  • Johnston, E.M. and Crawford, J. (1998) "Hematopoietic growth factors in the reduction of chemotherapeutic toxicity", Semin. Oncol. 25, 552-561.
  • Petrini, B., Wasserman, J., Hlomgren, H., Baral, E., Strender, L.E. and Wallgren, A. (1979) "Blood lymphocyte subpopulalions in breast cancer patients following post-operative adjuvant chemotherapy or radiotherapy", Clin. Exp. Immunol. 38, 361-365.
  • Sewell, H.F., Halbert, C.E., Robins, R.A., Calvin, A., Chan, S. and Blarney, R.W. (1993) "Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer", Int. J. Cancer 55, 735-738.
  • Mackall, C.L., Fleisher, T.A., Brown, M.R., Magrath, I.T., Shad, A.T., Hotowitz, M.E., Wexler, L.H., Adde, M.A., McClure, L.L. and Cress, R.E. (1994) "Lymphocyte depletion during treatment with intensive chemotherapy for cancer", Blood 84, 2221-2228.
  • Mackall, C.L. (1999) "T-Cell immunodeficiency following cytotoxic antineoplastic therapy: a review", Oncologist 4, 370-378.
  • Bruserud, O. (1998) "Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T-cells", Cancer Immunol. Immunother. 46, 221-228.
  • Windbichler, G.H., Hausmaninger, H., Slummvoll, W., Graf, A.H., Kami, C., Lahodny, J., Denison, U., Muller-Holzner, E. and Mann, C. (2000) "Interferon-gamma in the first-line therapy of ovarian cancer a randomized phase HI trial", Br. J. Caner 82, 1138-1144.
  • Cheson, B.D. (2002) "CHOP plus rituximab-balancing facts and opinion", N. Engl. J. Med. 346, 280-282.
  • Coiffier, B., Lepage, E., Briere, I., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulaid, P., Reyes, F., Ledcrlin, P. and Gisselbrecht, C. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N. Engl. J. Med. 346, 235-242.
  • Sievers, E.L. (2001) "Efficacy and safety of gemtuzumab ozogamicin in patterns with CD33-posilive acute myeloid leukaemia in first relapse", Expert Opin. Biol. Ther. 1, 893-901.
  • Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. and Appelbaum, F.R. (2001) "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse", J. Clin. Oncol. 19, 3244-3254.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.